With its eyes set on an IPO raise, InCarda unrolls mid-stage data backing inhaled arrhythmia drug

Max Gelman

Senior Editor

Working to craft an old arrythmia drug into a more user-friendly inhaled formulation, InCarda is expecting to use new Phase II data revealed Wednesday as …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With its eyes set on an IPO raise, InCarda unrolls mid-stage data backing inhaled arrhythmia drug

Max Gelman

Senior Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Will CRISPR matter?

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

With its eyes set on an IPO raise, In­Car­da un­rolls mid-stage da­ta back­ing in­haled ar­rhyth­mia drug

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

With its eyes set on an IPO raise, InCarda unrolls mid-stage data backing inhaled arrhythmia drug